Results 41 to 50 of about 11,087,757 (202)

DPP-4 inhibitor dose selection according to manufacturer specifications: A contemporary experience from UK general practice [PDF]

, 2019
Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests.
Tebboth, Abigail, Marcus, Michael W., Spanopoulos, Dionysis, Gollop, Nicholas D., Busse, Michael, Webb, Joanne   +5 more
core   +1 more source

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study

Diabetes, Metabolic Syndrome and Obesity, 2020
Takeshi Osonoi, Miyoko Saito, Naoya Koda, Satako Douguchi, Takako Nakano, Kensuke Ofuchi, Makoto Katoh Naka Kinen Clinic, Ibaraki, JapanCorrespondence: Makoto KatohNaka Kinen Clinic, 745-5 Nakadai, Naka-Shi, Ibaraki 311-0113, JapanTel +81-29-353-2800Fax +
Osonoi T, Saito M, Koda N, Douguchi S, Nakano T, Ofuchi K, Katoh M   +6 more
doaj  

DPP-4 Inhibitors: The Seinfeld of Oral Antihyperglycemics

The Canadian Journal of Hospital Pharmacy, 2016
-
Arden R, Barry, Ricky D, Turgeon
openaire   +3 more sources

Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects

Molecular Metabolism, 2017
Objective: Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) possess multiple bioactive isoforms that are rendered non-insulinotropic by the enzyme dipeptidyl peptidase-4 (DPP-4).
Tsuyoshi Yanagimachi, Yukihiro Fujita, Yasutaka Takeda, Jun Honjo, Hidemitsu Sakagami, Hiroya Kitsunai, Yumi Takiyama, Atsuko Abiko, Yuichi Makino, Timothy J. Kieffer, Masakazu Haneda   +10 more
doaj   +1 more source

Target trial emulation of DPP-4 Inhibitors in patients with T2DM for pulmonary tuberculosis: a nationwide observational data

BMC Medicine
Background Diabetes mellitus increases the risk of developing tuberculosis (TB) and negatively affects TB treatment outcomes. Dipeptidyl peptidase-4 (DPP-4) inhibitors are used in glycemic control but can also modulate immune pathways involved in immune ...
Yi-Geng Chen, James Cheng-Chung Wei, Fu-Shun Yen, Chen-Yu Sung, Yu-Han Huang, Teng-Shun Yu, Fuu-Jen Tsai, Chii-Min Hwu, Chih-Cheng Hsu   +8 more
doaj   +1 more source

Study on Anti-inflammatory and Anti-oxidative Stress Mechanism of Sitagliptin: a Dipeptidyl Peptidase-4 Inhibitor [PDF]

Zhongguo quanke yixue
The prevalence rate of type 2 diabetes is increasing year by year. It is known that oxidative stress and inflammation can participate in the occurrence and development of diabetes. Dipeptidyl peptidase-4 (DPP-4) inhibitors can enhance the incretin effect
ZHU Jing, XIE Ji, HU Xiaoxia
doaj   +1 more source

Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: A case report

American Journal of Ophthalmology Case Reports, 2023
Purpose: To report a rare Ocular Cicatricial Pemphigoid (OCP) case in a patient taking a Dipeptidyl Peptidase-4 Inhibitor (DPP-4 inhibitor), a medication used for the management of type 2 diabetes, for at least six years. Observations: A 64-year-old male
Akifumi Matsumoto, Hideki Fukuoka, Akiko Yoneda, Norihiko Yokoi, Chie Sotozono   +4 more
doaj   +1 more source

DPP-4 inhibition protects human umbilical vein endothelial cells from hypoxia-induced vascular barrier impairment

Journal of Pharmacological Sciences, 2017
Dipeptidyl peptidase-4 (DPP-4) inhibitors are relatively new class of anti-diabetic drugs. Some protective effects of DPP-4 on cardiovascular disease have been described independently from glucose-lowering effect.
Naoko Hashimoto, Kento Ikuma, Yui Konno, Masanori Hirose, Hiroyuki Tadokoro, Hiroshi Hasegawa, Yoshio Kobayashi, Hiroyuki Takano   +7 more
doaj   +1 more source

DPP-4 activity.

, 2013
DPP-4 activity was measured 24 h after administration of the respective compounds (N = 13–17 per DPP-4 inhibitor group, control N = 57; no difference was made between sham-operated rats and 5/6N groups). All drugs showed a significant inhibition of DPP-4
Berthold Hocher (311916), Markus Alter (339018), Frank Runge (339021), Lyubov Chaykovska (339015), Holger Fuchs (339020), Susi Heiden (339019), Jan Rahnenführer (339017), Thomas Klein (121443), Karoline von Websky (311911)   +8 more
core   +1 more source

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms

Frontiers in Pharmacology, 2017
Diabetes mellitus has been demonstrated to be closely associated with osteoporosis. Accordingly, hypoglycemic therapy is considered effective in treating metabolic bone disease.
Yinqiu Yang, Chenhe Zhao, Jing Liang, Mingxiang Yu, Xinhua Qu   +4 more
doaj   +1 more source